newsfilter
← Latest News
PR Newswire·

Seqirus Presents New Phase 3 Clinical Data Supporting Use of Cell-Based Seasonal Influenza Vaccine in Children Six Months Through <4 Years of Age

SUMMIT, N.J., May 3, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, presented new Phase 3 clinical data demonstrating that the company's cell-based quadrivalent seasonal influenza vaccine (QIVc) was as safe and immunogenic as a st